Johnson & Johnson Deal History & Licensing Activity
Johnson & Johnson is a large pharma headquartered in US. Over the past three years, Johnson & Johnson has been involved in 11 licensing and acquisition transactions, with a primary focus on Other (5 deals). The company currently has 50 active clinical trials, primarily in Autoimmune.
Deals (12mo)
4
Active Trials
50
Top Modality
Other
Focus Area
Autoimmune
Johnson & Johnson Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Johnson & Johnson in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed | Sail Biomedicines, Inc. | CAR-T | Preclinical | option | Jul 30, 2026 |
| botaretigene sparoparvovec (bota-vec) | MeiraGTx | Gene Therapy | Phase 3 | acquisition | Apr 16, 2026 |
| JNJ-4804 | Royalty Pharma plc | Other | Unknown | co development | Mar 30, 2026 |
| HLD-0915 (RIPTAC platform) | Halda Therapeutics | Small Molecules | Phase 1 | acquisition | Nov 17, 2025 |
Johnson & Johnson Pipeline Focus
Therapeutic areas and modalities where Johnson & Johnson is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Johnson & Johnson Strategic Signals
Key indicators of Johnson & Johnson's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Johnson & Johnson Clinical Pipeline
Johnson & Johnson has 50 active clinical trials across 8 development phases.
7
Unknown
6
Not Applicable
2
Phase 4
8
Phase 1
2
Phase 1/2
7
Phase 2
2
Phase 2/3
16
Phase 3
See How Your Asset Matches Johnson & Johnson's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Johnson & Johnson Licensing & Deal Activity
Johnson & Johnson is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 11 deals over the past three years, Johnson & Johnson ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Johnson & Johnson include Autoimmune (11 deals and trials), Solid Tumors (10 deals and trials), Hematological Malignancies (6 deals and trials), and Cardiovascular (5 deals and trials). In terms of modality, Johnson & Johnson has shown particular interest in other, small molecules, gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Johnson & Johnson and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Johnson & Johnson's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.